Diabetes drug growth helps spur AstraZeneca's top line modestly higher, however higher costs and patent expirations take their toll.
Sean Williams, The Motley Fool, The Motley Fool
Thu, 04/24/2014 - 5:36am
Diabetes drug growth helps spur AstraZeneca's top line modestly higher, however higher costs and patent expirations take their toll.